Funding for this research was provided by:
National Institutes of Health (P50 CA88843, P30 CA006973)
Avon Foundation for Women (02-2010-048)
Susan G. Komen (LRTSTBCR07)
Breast Cancer Research Foundation (316-2016)
Merck (drug supply)
Cindy Rosencrans fund for TNBC (80022485)
Abraxis (drug supply)
Received: 5 September 2017
Accepted: 7 September 2017
First Online: 16 September 2017
Compliance with ethical standards
: Women enrolling in the study signed an informed consent approved by the Institutional Review Boards of participating institutions.
: VS has received research Grants from Merck, Celgene Corporation, Abbvie, Pfizer, Novartis, Medimmune, and Puma Biotechnology. RC has received research Grants from Novartis, Puma Biotechnology, Genentech, Merrimack, Clovis, Merck. AMS has received consulting fees from Eli Lilly and Co., and Pfizer. SS has received research Grants from AVON Foundation, Grants, licensing/royalty fees and consulting fees from Cepheid for QM-MSP and cMethDNA assays. MJF has received licensing/royalty fees and consulting fees from Cepheid. The remaining authors have no conflicts of interest to disclose.